TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2009

Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.

Stuart Salmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.